Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C25H24F3N3O2 |
| Molecular Weight | 455.4722 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)C[C@H]1CC[C@@H](CC1)C2=CC=C(C=C2)C3=NC=C(NC4=CN=C(C=C4)C(F)(F)F)C=C3
InChI
InChIKey=GXALXAKNHIROPE-QAQDUYKDSA-N
InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33)/t16-,17-
DescriptionCurator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800030516
Curator's Comment: Description was created based on several sources, including
http://adisinsight.springer.com/drugs/800030516
LCQ908 (Pradigastat) is a diacylglycerol acyltransferase-1 (DGAT-1) inhibitor. DGAT-1 is one of the two DGAT enzymes that catalyse the formation of triglycerides from diacylglycerol and acyl- coenzyme A. DGAT-1 catalyses the final committed step in processing dietary fatty acids into triglycerides carried on chylomicrons for transport around the body. Pradigastat may decrease the level of triglycerides in the blood and is intended for the first line treatment of FCS. It is administered orally at 10-40mg daily in addition to a low fat diet. Pradigastat is also in phase II clinical trials for type 2 diabetes and severe hypertriglyceridaemia (familial hyperchylomicronaemia phenotypes I and V). Pradigastat is a designated orphan drug in the EU. In a phase III clinical trial.
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
184 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25627776 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1065 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25854859 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
10500 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27274009 |
115 mg single, intravenous dose: 115 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
37200 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25627776 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18561 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25854859 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
428000 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27274009 |
115 mg single, intravenous dose: 115 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
145 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25627776 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
80.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25854859 |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: MALE food status: FASTED |
|
109 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27274009 |
115 mg single, intravenous dose: 115 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.6% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25627776 |
40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered: |
PRADIGASTAT plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
300 mg single, oral Highest studied dose |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: FASTED Sources: |
|
115 mg single, intravenous Studied dose Dose: 115 mg Route: intravenous Route: single Dose: 115 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects. | 2015-09 |
|
| Effect of pradigastat, a diacylglycerol acyltransferase 1 inhibitor, on the pharmacokinetics of a combination oral contraceptive in healthy female subjects. | 2015-04 |
Patents
Sample Use Guides
Experimental: LCQ908 (Pradigastat) 20 mg
In period II (0-12 weeks) double-blind treatment: one LCQ908 (Pradigastat) 20 mg active tablet, once daily
In period III (12-52 weeks) double blind treatment: Without down titration, the period II dosing regimen will follow. Following decision to down titrate: one LCQ908 (Pradigastat) 10 mg active tablet, once daily.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
335711
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL2364624
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
956136-95-1
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
100000183196
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
C166592
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
DTXSID401026085
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
2U23G6VNUZ
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
DB12866
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
9544
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
SUB197600
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
53387035
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY | |||
|
AB-08
Created by
admin on Mon Mar 31 20:33:00 GMT 2025 , Edited by admin on Mon Mar 31 20:33:00 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
